4-(3-hydrazinylpropyl)morpholine | 59749-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(3-hydrazinylpropyl)morpholine
• 英文别名: 4-(3-hydrazino-propyl)-morpholine；n-(3-hydrazinopropyl)morpholine；3-morpholinopropylhydrazine；3-morpholin-4-ylpropylhydrazine
• CAS: 59749-74-5
• 化学式: C₇H₁₇N₃O
• mdl: MFCD07786280
• 分子量: 159.231
• InChiKey: RPKHDUBCKJZLAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 2-(1-chloronaphthalen-2-yl)ethanimidate 、 4-(3-hydrazinylpropyl)morpholine 以34%的产率得到
  参考文献：
  名称：

  MCCARTHY, J. R.;WRIGHT, D. L.;SCHUSTER, A. J.;ABDALLAH, ABDUL, H.;SHEA, P+, J. MED. CHEM., 1985, 28, N 11, 1721-1727

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(3-氯丙基)吗啉盐酸盐 、 肼 以56%的产率得到
  参考文献：
  名称：

  KRAPCHO J.; TURK C. F., J. MED. CHEM., 1979, 22, NO 2, 207-210

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS)<br/>[FR] INHIBITEURS DE LA DÉMÉTHYLASE (LSD1) SPÉCIFIQUE D'UNE LYSINE D'HISTONE ET D'HISTONES DÉSACÉTYLASES (HDAC)
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2015134973A1

  公开（公告）日：2015-09-11

  A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases.

  提供了一系列苯妥英类似物，包括一个连接到芳香基团的苯妥英骨架，并且它们作为赖氨酸特异性去甲基化酶1（LSD1）和/或一个或多个组蛋白去乙酰化酶（HDACs）的抑制剂的用途。目前披露的苯妥英类似物对LSD1相对于MAO和LSD2酶表现出高效性和选择性，并且在几种癌细胞系中表现出体积、以及基因特异性组蛋白甲基化变化，抗增殖活性，并对氧化应激作出神经保护。因此，目前披露的苯妥英类似物可用于治疗与LSD1和/或HDACs相关的疾病、症状或障碍，包括但不限于癌症和神经退行性疾病。
• Bicyclic pyrazolines, potential central nervous system depressants and antiinflammatory agents
  作者：John Krapcho、Chester F. Turk

  DOI：10.1021/jm00188a018

  日期：1979.2

  The synthesis and CNS activity of a series of 34 substituted bicyclic pyrazolines are described. Ten of these compounds were also screened for antiinflammatory activity. One of the compounds (15) exhibited significant antiinflammatory activity in the carrageenan-induced edema test.

  描述了一系列34个取代的双环吡唑啉的合成和CNS活性。还筛选了其中的10种化合物的抗炎活性。一种化合物（15）在角叉菜胶诱导的水肿试验中显示出显着的抗炎活性。
• [EN] FUNGICIDAL OXIMES AND HYDRAZONES<br/>[FR] OXIMES ET HYDRAZONES FONGICIDES
  申请人：DU PONT

  公开号：WO2011146182A1

  公开（公告）日：2011-11-24

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G, W2 and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention. Also disclosed are compounds of Formula 1A including all stereoisomers, N-oxides, and salts thereof, wherein E, X, G and Z1 are as defined in the disclosure. Also disclosed is the use of the compounds of Formula 1A as intermediates for preparing compounds of Formula 1.

  揭示了Formula 1的化合物，包括所有立体异构体、N-氧化物和盐类，其中E、X、G、W2和Z如披露中所定义。还披露了含有Formula 1化合物的组合物以及用于控制由真菌病原体引起的植物疾病的方法，包括施用本发明的化合物或组合物的有效量。还披露了包括所有立体异构体、N-氧化物和盐类的Formula 1A的化合物，其中E、X、G和Z1如披露中所定义。还披露了将Formula 1A的化合物用作制备Formula 1化合物的中间体的用途。
• [EN] SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE NADPH OXYDASE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2018203298A1

  公开（公告）日：2018-11-08

  The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

  本申请涉及取代的融合杂环芳基和杂环化合物，用作烟酰胺腺嘌呤二核苷酸磷酸酶抑制剂（NADPH氧化酶抑制剂），其制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物在治疗或预防由NADPH氧化酶介导的各种疾病、症状和/或障碍中的用途。 (分子式I)
• Basically-substituted tricyclic pyrazoles useful as antiinflammatory
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04173634A1

  公开（公告）日：1979-11-06

  Compounds of the structure ##STR1## are provided, wherein n is 1, 2 or 3, m is 2, 3 or 4, X and Y may be the same or different and are hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio or trifluoromethyl, and B is di-lower alkylamino, piperidino, pyrrolidino, morpholino, or N-lower alkylpiperazino and pharmaceutically acceptable acid-addition salts thereof. These compounds have been found to be useful as antiinflammatory agents.

  提供了结构为##STR1##的化合物，其中n为1、2或3，m为2、3或4，X和Y可以相同或不同，可以是氢、卤素、低级烷基、低级烷氧基、低级烷硫基或三氟甲基，B为二低级烷基氨基、哌啶基、吡咯烷基、吗啉基或N-低级烷基哌嗪基及其药学上可接受的酸加合物盐。发现这些化合物可用作抗炎药物。